Table 5:
Baseline characteristics after propensity score matching
| Characteristics | Open approach Matched patients (n = 30) |
VATS approach Matched patients (n = 30) |
P-value | Absolute standardized difference (%) |
|---|---|---|---|---|
| Female sex (n, %) | 13 (43) | 12 (40) | 0.79 | 6.7 |
| Age (mean ± SD) (years) | 60.7 ± 8.9 | 61.6 ± 11.4 | 0.72 | 9.3 |
| Ethnicity (n, %) | 0.15 | |||
| White | 26 (87) | 27 (90) | 9.1 | |
| Black | 4 (13) | 1 (3) | 29.0 | |
| Native American | 0 (0) | 2 (7) | 45.9 | |
| FEV1 (mean ± SD) (% predicted) | rm14 | 70.4 ± 20.5 | 0.47 | 20.5 |
| DLCO (mean ± SD) (% predicted) | 68.0 ± 21.5 | 71.3 ± 17.0 | 0.54 | 17.7 |
| History of diabetes (n, %) | 5 (17) | 4 (13) | 0.72 | 9.2 |
| Renal insufficiency (n, %) | 0 (0) | 0 (0) | 1.00 | 0.0 |
| COPD (n, %) | 10 (33) | 10 (33) | 1.00 | 0.0 |
| Prior thoracic surgery (n, %) | 5 (17) | 8 (27) | 0.35 | 22.9 |
| Clinical stage prior to induction therapya (n, %) | 0.51 | |||
| IA | 0 (0) | 0 (0) | 0.0 | |
| IB | 0 (0) | 1 (3) | 27.6 | |
| IIA | 2 (7) | 2 (7) | 0.0 | |
| IIB | 4 (13) | 1 (3) | 29.6 | |
| IIIA | 15 (50) | 18 (60) | 20.3 | |
| IIIB | 1 (3) | 1 (3) | 0.0 | |
| IV | 6 (20) | 4 (13) | 25.9 | |
| Unknown | 2 (7) | 3 (10) | 13.8 | |
| Congestive heart failure (n, %) | 0 (0) | 0 (0) | 1.00 | 0.0 |
| Cerebrovascular disease (n, %) | 1 (3) | 0 (0) | 0.31 | 21.7 |
| Coronary artery disease (n, %) | 3 (10) | 5 (17) | 0.45 | 18.0 |
| History of cancer (n, %) | 5 (17) | 5 (17) | 1.00 | 0.0 |
| History of smoking | 27 (90) | 28 (93) | 0.64 | |
| Radiation (n, %) | 5(17) | 5 (17) | 1.00 | 7.4 |
| Transient ischemic attack/cerebrovascular accident (n, %) | 0 (0) | 0 (0) | 1.00 | 0.0 |
| Central versus peripheral tumour (n, %) | 0.77 | |||
| Central | 9 (30) | 8 (27) | 7.5 | |
| Peripheral | 21 (70) | 22 (73) | 7.5 | |
| Operative year | 0.061 | |||
| 1996–2001 | 0 (0) | 1 (3) | 10.1 | |
| 2002–07 | 11 (37) | 10 (33) | 7.5 | |
| 2008–12 | 19 (63) | 19 (63) | 0.0 | |
| Pathological T status (n, %) | 0.49 | |||
| T0 | 8 (27) | 6 (20) | 15.3 | |
| T1 | 6 (20) | 10 (33) | 29.5 | |
| T2 | 11 (37) | 9 (30) | 14.6 | |
| T3 | 5 (17) | 4 (13) | 9.5 | |
| T4 | 0 (0) | 1 (3) | 25.6 | |
| Pathological N status (n, %) | 0.78 | |||
| N0 | 21 (70) | 23 (77) | 14.1 | |
| N1 | 3 (10) | 3 (10) | 0.0 | |
| N2 | 6 (20) | 4 (13) | 16.6 | |
| Pathological M status (n, %) | 0.69 | 13.6 | ||
| M0 | 26 (87) | 27 (90) | ||
| M1 | 4 (13) | 3 (10) | ||
| Pretreatment histology (n, %) | 0.36 | |||
| Adenocarcinoma | 15 (50) | 12 (40) | 20.2 | |
| Adenosquamous | 1 (3) | 1 (3) | 0.0 | |
| Squamous | 5 (17) | 11 (37) | 42.6 | |
| Large cell | 4 (13) | 1 (3) | 45.2 | |
| Non-small cell, not otherwise specified | 5 (17) | 5 (17) | 0.0 |
FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide; COPD: chronic obstructive pulmonary disease; VATS: video-assisted thoracoscopic surgery; SD: standard deviation.
aData only available for 56 of 60 patients (open n = 28, VATS n = 28).